Many patients with ER+ HER2− primary breast cancer are being deferred from surgery to
neoadjuvant endocrine therapy (NeoET) during the COVID-19 pandemic. We have collated …

Neoadjuvant therapy is commonly used in patients with locally advanced or inoperable
breast cancer (BC). Neoadjuvant chemotherapy (NACT) represents an established …

The treatment of breast cancer is driven by subtype classification, of which the assessment
of hormone receptor status is one of the important determinants of therapy. The use of …

Background Neoadjuvant treatment is increasingly one of the preferred therapeutic options
for early breast cancer and may have some unique outcomes, such as identifying predictive …

Purpose Despite increasing awareness of accrual challenges, it is unknown if accrual of
older patients to breast cancer treatment trials is improving. Methods We examined accrual …

Current treatment of breast cancer incorporates clinical, pathological and molecular data.
Oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor …

Significant endocrine therapy–resistant tumor proliferation is present in≥ 20% of estrogen
receptor–positive (ER+) primary breast cancers and is associated with disease recurrence …

Abstract Introduction OncotypeDX© Recurrence Score (RS) is a multigene panel used to aid
therapeutic decision making in early-stage, estrogen receptor positive (ER+)/human …

Background Neoadjuvant endocrine therapy (NET) is effective in downstaging large
hormone receptor-positive (HR+) breast cancers and increasing rates of breast-conserving …

Over the last few years, the indication for chemotherapy use in HR+/HER2− early BC has
been significantly modified by the introduction of gene-expression profiling. In the adjuvant …